These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 15456476)

  • 1. Recombinant factor VIIa: a general hemostatic agent? Not yet.
    Levi M
    J Thromb Haemost; 2004 Oct; 2(10):1695-7. PubMed ID: 15456476
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant factor VIIa: a general hemostatic agent? Yes.
    Roberts HR
    J Thromb Haemost; 2004 Oct; 2(10):1691-4. PubMed ID: 15456475
    [No Abstract]   [Full Text] [Related]  

  • 3. Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders.
    Croom KF; McCormack PL
    BioDrugs; 2008; 22(2):121-36. PubMed ID: 18345709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant factor VIIa: a review on its clinical use.
    Franchini M
    Int J Hematol; 2006 Feb; 83(2):126-38. PubMed ID: 16513530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII.
    Liebman HA; Chediak J; Fink KI; Galvez AG; Shah PC; Sham RL
    Am J Hematol; 2000 Mar; 63(3):109-13. PubMed ID: 10679799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant-activated coagulation factor VIIa (NovoSeven): current development.
    Weiskopf RB
    Vox Sang; 2007 May; 92(4):281-8. PubMed ID: 17456151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U; Erhardtsen E
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant factor VIIa, its clinical properties, and the tissue factor pathway of coagulation.
    Bosinski TJ; El Solh AA
    Mini Rev Med Chem; 2006 Oct; 6(10):1111-7. PubMed ID: 17073711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NovoSeven for non-hemophilia hemostasis.
    Med Lett Drugs Ther; 2004 Apr; 46(1181):33-4. PubMed ID: 15114252
    [No Abstract]   [Full Text] [Related]  

  • 10. Challenges in the therapeutic use of a "so-called" universal hemostatic agent: recombinant factor VIIa.
    Hoots WK
    Hematology Am Soc Hematol Educ Program; 2006; ():426-31. PubMed ID: 17124094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promising coagulation factor VIII bypassing strategies for patients with haemophilia A.
    Duan X; Tang M; Zhang J; Yu H; Xu R
    Blood Coagul Fibrinolysis; 2014 Sep; 25(6):539-52. PubMed ID: 24614429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The concept of recombinant factor VIIa megadose for treating bleeding episodes in high-titer inhibitor patients with hemophilia: toward an expanding indication?
    Negrier C
    J Thromb Haemost; 2003 Mar; 1(3):423-4. PubMed ID: 12871444
    [No Abstract]   [Full Text] [Related]  

  • 13. Antidotes to haemorrhage: recombinant factor VIIa.
    Kessler CM
    Best Pract Res Clin Haematol; 2004 Mar; 17(1):183-97. PubMed ID: 15171966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proceedings of the 6th Novo Nordisk Symposium on Treatment of Bleeding and Thrombotic Disorders. Copenhagen, Denmark, May 3-4, 2001.
    Semin Hematol; 2001 Oct; 38(4 Suppl 12):1-50. PubMed ID: 11840984
    [No Abstract]   [Full Text] [Related]  

  • 15. Factor VII deficiency and its treatment in delivery with recombinant factor VII.
    Pehlivanov B; Milchev N; Kroumov G
    Eur J Obstet Gynecol Reprod Biol; 2004 Oct; 116(2):237-8. PubMed ID: 15358473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant coagulation factor VIIa: from the concept to clinical application in hemophilia treatment in 2000.
    Hedner U
    Semin Thromb Hemost; 2000; 26(4):363-6. PubMed ID: 11092209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant FVIIa.
    Hedner U
    Vox Sang; 2004 Jul; 87 Suppl 2():25-8. PubMed ID: 15209873
    [No Abstract]   [Full Text] [Related]  

  • 18. Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors.
    Stephens JM; Joshi AV; Sumner M; Botteman MF
    Expert Opin Pharmacother; 2007 Jun; 8(8):1127-36. PubMed ID: 17516876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease.
    Brinkhous KM; Hedner U; Garris JB; Diness V; Read MS
    Proc Natl Acad Sci U S A; 1989 Feb; 86(4):1382-6. PubMed ID: 2784006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of hemostatic status in four patients being treated with recombinant factor VIIa.
    Carr ME; Martin EJ; Kuhn JG; Ambrose H; Fern S; Bryant PC
    Clin Lab; 2004; 50(9-10):529-38. PubMed ID: 15481628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.